Editorials

Can Large Simple Trials Help Us Understand When and How to Use Generic Drugs for Uncommon Diseases?
J.A. Molitor, D.L. Demets ........................................... 539

Quality Guidelines for Systemic Lupus Erythematosus: Slow But Steady Progress D.J. Wallace ................. 542

C'mon, CAM R.S. Panush ............................................. 544

The Role of Complementary and Alternative Medicine (CAM) in Rheumatology — It's Time for Integrative Medicine A. Michalsen ............................................. 547

Review

Classification, Diagnosis, and Management of Idiopathic Inflammatory Myopathies I.N. Lazarou, P-A. Guerne ........ 550

Articles


Clinical Response Within 12 Weeks as a Predictor of Future Low Disease Activity in Patients with Early RA: Results from the TEAR Trial J.R. Curtis, T. McVie, T.R. Mikuls, et al ............. 572

Efficacy and Safety of Belimumab in RA: A Phase II, Randomized, Double-blind, Placebo-controlled, Dose-ranging Study W. Stohl, J.T. Merrill, J.D. McKay, et al ............. 579

Evaluation of Serum Biomarkers Associated with Radiographic Progression in MTX-naive RA Patients Treated with MTX or Golimumab C. Wagner, D. Chen, H. Fan, E.C. Hsia, M. Mack, P. Emery, R.M. Fleischmann .... 590

Safety of Rituximab in Combination with Other Biologic DMARD in RA: An Open-label Study W.F.C. Rigby, P.J. Mease, E. Olech, M. Ashby, S. Tole ..................................................... 599

Longterm Outcomes and Treatment After Myocardial Infarction in Patients with RA S.S. McCoy, C.S. Crowson, H. Maradit-Kremers, et al ....... 605

Trends in Serious Infections in RA O.M. Ni Mhuircheartaigh, E.L. Matteson, A.B. Green, C.S. Crowson ............................................. 611


Early Local Swelling and Tenderness Are Associated with Large-joint Damage After 8 Years of Treatment to Target in Patients with Recent-onset RA M. van den Broek, L. Dirven, H.M. Kroon, et al ........... 624

Recommendations for Frequency of Visits to Monitor SLE in Asymptomatic Patients: Data from an Observational Cohort Study D.D. Gladman, D. Ibañez, I. Ruíz, M.B. Urowitz ........ 630

Progression of Nailfold Microvascular Damage and ANA Pattern in SSc A. Sull, B. Ruario, V. Smith, et al ......................................... 634


Application and Modifications of Minimal Disease Activity Measures for Patients with PsA Treated with Adalimumab: Subanalyses of ADEPT P.J. Mease, M. Heckaman, S. Kary, H. Kupper .......................... 647

Periarticular Bone Gain at PIP Joints and Changes in Bone Turnover Markers in Response to TNF Inhibitors in Rheumatoid and Psoriatic Arthritis A. Szentpetery, M.J. McKenna, B.F. Murray, et al ........ 653

Gene Expression of Catalytic Proteasome Subunits and Resistance Toward Proteasome Inhibition of B Lymphocytes from Patients with Primary SS L. Martinez-Gamboa, K. Lesemann, U. Kuckelkum, et al ........ 663
